Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03416153 · ClinicalTrials.gov registry record · Phase 2
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
A Phase 2 study of Oropharynx Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT03416153: Completed Phase 2 study of Oropharynx Cancer, sponsored by University of Michigan Rogel Cancer Center.
NCT03416153 is a Phase 2 study of Oropharynx Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 91 participants, below the 129-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03416153, a Phase 2 study of Oropharynx Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
Primary Outcome
RECIST (Response Evaluation Criteria In Solid Tumors) will be used to evaluate response and recurrence. All patients will be analyzed together as the goal of the study is to estimate risk of LRR in this patient population treated with this particular strategy in which some patients continue to receive standard therapy while others are de-escalated. Results will also be estimated and reported separately for patients receiving standard or de-escalated therapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiation Therapy
Study Locations (2)
Michigan
- University of Michigan Hospital - Ann Arbor
- VA Ann Arbor Healthcare System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2025-05-05 |
| Phase | Phase 2 |
What the finished NCT03416153 record still lists
NCT03416153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 129-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03416153 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03416153 about?
NCT03416153 is a clinical study titled "Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer". This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
What is the current status of trial NCT03416153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2018-05-21. Estimated completion is 2025-05-05.
What conditions does trial NCT03416153 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT03416153?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03416153?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03416153 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03416153's enrollment target sits among peer trials
91 7th of 26 higher than 20 of 26 other Oropharynx Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharynx Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI